Medigene AG: Medigene collaborates with RXi Pharmaceuticals to further sharpen its therapeutic T cells
- Synergies between the recombinant T cell technologies of Medigene and self-delivering RNAi technologies from RXi Pharm…
- Synergies between the recombinant T cell technologies of Medigene and self-delivering RNAi technologies from RXi Pharm…
- Automated in vitro testing could reveal better neoantigens that activate more effective killer T cell responses - Two…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) announced that researchers from Oslo University Hospital presented an up…
T cell receptor (TCR) therapeutic candidates against four targets to be generated using Medigene's proprietary TCR techn…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company focusing on the development of T…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company focusing on the development of T…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology company, announced the treatment start o…
Das Immunonkologie-Unternehmen Medigene AG (MDG1, Frankfurt, Prime Standard) gibt bekannt, dass in ihrer klinischen Phas…
Patientenrekrutierung für klinische Phase I-Teil der Phase I/II-DC-Vakzine Studie erfolgreich abgeschlossen Patienten…
Patient recruitment for clinical Phase I in Phase I/II DC vaccine study successfully completed All patients treated with…